Prevalencia de esclerosis múltiple en Ecuador

Abad, Patricio; Pérez, María; Castro, Esteban Ron; Alarcón, T.; Santibáñez, Rocío; Díaz, Francisco

doi:10.1016/j.nrl.2009.12.005

Cited by 34 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After full-text review, 14 met inclusion criteria and were selected for data abstraction and analysis of incidence-prevalence (Figure 1). 14–37 Information was obtained from nine countries (Figure 2). Regarding incidence, we found five studies (French West Indies, Argentina and Panama) that evaluated this issue.…”

Section: Resultsmentioning

confidence: 99%

Multiple sclerosis epidemiology in Latin America: An updated survey

Cristiano¹,

Rojas

2017

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Novel epidemiological data have appeared in recent years in Latin America (LATAM). The objective of this study was to perform an updated systematic review of the epidemiology of the disease reported in LATAM.MethodsWe conducted a systematic review of published epidemiological articles from January 1995 to December 2016.ResultsIncidence data were found in four studies and ranged from 0.3 to 3 annual cases per 100,000 person-years. Prevalence was reported in 13 studies and ranged from 0.83 to 38.2 cases per 100,000 inhabitants. Two studies showed an increase in prevalence and incidence in the last five years in specific regions.ConclusionThe study provides updated information on epidemiological features of MS in the region. The frequency reported is lower compared with some European and North American countries; however, due to recent observations, studies including follow-up assessment of prevalence and incidence should be conducted in the region.

show abstract

Section: Resultsmentioning

confidence: 99%

Multiple sclerosis epidemiology in Latin America: An updated survey

Cristiano¹,

Rojas

2017

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

show abstract

“…The estimated 2016 cumulative prevalence of MS in PR is the highest among countries in the Caribbean and Latin America [16]. Prevalence estimates in this region ranges from a low of 0.75/100,000 in Guayaquil, Ecuador [32] to a high of 38.2/100,000 in Buenos Aires, Argentina [18]. The estimated prevalence of MS in PR resembles prevalence estimates since 2001 from Spain and Portugal [33] ranging from 41.7/100,000 [34] to 78.7/100,000 [35].…”

Section: Discussionmentioning

confidence: 99%

Increasing Incidence and Prevalence of Multiple Sclerosis in Puerto Rico (2013–2016)

et al. 2017

View full text Add to dashboard Cite

Background: The incidence of multiple sclerosis (MS) has been increasing worldwide over the past decades. However, this upward trend has not been examined at the country level in Latin America and the Caribbean (LAC). The aims of this study are to examine trends of MS incidence over 4 years and to provide age- and gender-standardized incidence rate estimates for a Caribbean island. Methods: Data from the Puerto Rico (PR) MS Foundation’s registry was used to identify all newly diagnosed MS cases between 2013 and 2016. MS patients were 18 years and older and met the 2010 revised McDonald criteria. Age- and gender-standardized incidence rates were estimated. Results: A total of 583 new MS cases were diagnosed in PR from 2013 to 2016. The age- and gender-standardized MS incidence rate for PR increased from 6.1/100,000 in 2013 to 6.7/100,000 in 2016. The annual age-standardized MS incidence rates for females rose from 8.4/100,000 in 2013 to 9.8/100,000 in 2016 and were higher than males, which remained around 3.7/100,000. Conclusion: Incidence estimates for PR were higher than other LAC countries but consistent with MS increases in other world regions. Our findings tend to rule out several prior potential environmental explanations for high MS incidence rates.

show abstract

“…The incidence is between 0.6 and 2.2 per 100,000 inhabitants, which in general terms can be regarded as a low-prevalence disease [1,2,3,4,5,6]. There is scarce information on treatment availability, coverage and therapeutic effectiveness, treatment guides, the existence of academic, patients’ and family associations, participation in clinical trials and national and international collaborative research projects or the disease burden.…”

Section: Introductionmentioning

confidence: 99%